Neuromodulation : journal of the International Neuromodulation Society · 2025
Technical and Clinical Overview: Spinal Cord Stimulation.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Falowski Steven, Ali Rushna, Sweet Jennifer, Mackel Charles, Kesarwani Rohit, Arle Jeffrey, Larkin Michael B, Pinckard-Dover Heather N, Stone Lauren, Nerison Caleb, Ben Haim Sharona, Rosenow Joshua, Viswanathan Ashwin, Petersen Erika, Lad Nandan, Schwalb Jason, Raslan Ahmed
Аннотация
INTRODUCTION: Spinal cord stimulation (SCS) has evolved from simple systems with limited waveforms and electrode configurations to modern, complex systems developed to exert specific effects on the central nervous system. The growth in this space has focused on improving therapy delivery, enhancing tolerance, increasing longevity, and expanding indications.
MATERIALS AND METHODS: Members of the American Association of Neurological Surgeons/Congress of Neurological Surgeons Pain Section evaluate current technologies on the market to define the state of implants and devices. The study also discusses each manufacturer's scientific evidence and waveforms, in addition to reviewing their current publications and support data.
RESULTS: The SCS devices of all Food and Drug Administration-approved companies are reviewed, including Medtronic, Abbott, Boston Scientific, Saluda, Biotronik, and Nevro.
CONCLUSION: Technology and innovation are evolving rapidly in the field of spinal neuromodulation space. Clinical trials providing level 1 evidence have followed suit and indicated the superiority of this therapy to medical management in treating patients with different painful conditions.
MATERIALS AND METHODS: Members of the American Association of Neurological Surgeons/Congress of Neurological Surgeons Pain Section evaluate current technologies on the market to define the state of implants and devices. The study also discusses each manufacturer's scientific evidence and waveforms, in addition to reviewing their current publications and support data.
RESULTS: The SCS devices of all Food and Drug Administration-approved companies are reviewed, including Medtronic, Abbott, Boston Scientific, Saluda, Biotronik, and Nevro.
CONCLUSION: Technology and innovation are evolving rapidly in the field of spinal neuromodulation space. Clinical trials providing level 1 evidence have followed suit and indicated the superiority of this therapy to medical management in treating patients with different painful conditions.